Grey Wolf Therapeutics Limited

Grey Wolf Therapeutics Limited is a biotechnology company headquartered in Oxford, UK, founded in 2017 by Peter Joyce and Tom McCarthy. The company is developing a new therapeutic class that modulates antigen presentation to alter how cells appear to the immune system, aiming to treat cancers and autoimmune disorders. Its clinical assets include GRWD5769 in oncology and GRWD0715 in autoimmunity, both in Phase 1/2 trials.

Grey Wolf Therapeutics was founded in 2017 by Peter Joyce, former R&D Lead at Vertex Pharmaceuticals, and Tom McCarthy, former President and CEO of Spinifex Pharmaceuticals. The company is headquartered in Oxford, UK, and is developing oral small molecules that modulate antigen presentation. Its clinical assets in oncology (GRWD5769) and autoimmunity (GRWD0715) are in Phase 1/2 trials. The company has active discovery and development programs across oncology and autoimmunity.

Developing a new therapeutic class by modulating antigen presentation to treat cancers and autoimmune disorders.

• GRWD5769

  Clinical asset in oncology in Phase 1/2 trials.

• GRWD0715

  Clinical asset in autoimmunity in Phase 1/2 trials.

1. 1Greywolf Therapeuticsgreywolftherapeutics.com
2. 2Greywolf – About usgreywolftherapeutics.com